-
Mashup Score: 4What to Know About Hypertrophic Cardiomyopathy in Kids - 1 month(s) ago
The condition is rare in kids, yet experts say it’s one of the leading causes of death in young athletes.
Source: TIME.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 14Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy | HFSA - 1 month(s) ago
This virtual seminar will feature a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.
Source: hfsa.orgCategories: General Medicine News, Partners & KOLsTweet-
Mavacamten, aficamten, ranolazine, and evolving gene therapies... what are the current and emerging therapies to treat Hypertrophic cardiomyopathy? Join us live Nov 2 at 6 PM ET and OnDemand afterwards for a virtual seminar to find out! #HCM Register now: https://t.co/V2gzoofy84 https://t.co/gvelXUC0DT
-
-
Mashup Score: 4Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy | HFSA - 2 month(s) ago
This virtual seminar will feature a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.
Source: hfsa.orgCategories: General Medicine News, Partners & KOLsTweet-
Mavacamten, aficamten, ranolazine, and evolving gene therapies... what are the current and emerging therapies to treat Hypertrophic cardiomyopathy? Join us live Nov 2 at 6 PM ET and OnDemand afterwards for a virtual seminar to find out! #HCM Register now: https://t.co/V2gzoofy84 https://t.co/gvelXUC0DT
-
-
Mashup Score: 14Cleveland Clinic Performs World’s First In-Human Gene Therapy for Hypertrophic Cardiomyopathy - 2 month(s) ago
Patient is first person dosed in clinical trial
Source: newsroom.clevelandclinic.orgCategories: Expert Picks, Latest HeadlinesTweet-
Cleveland Clinic Performs World’s First In-Human Gene Therapy for Hypertrophic Cardiomyopathy (#HCM ) The gene to delivers MYBPC3 to the heart muscle through a one-time infusion of TN-201, a first-in-class adeno-associated virus-based gene therapy. https://t.co/pzpcOZJkXo
-
-
Mashup Score: 7When to Order an Echocardiogram to Evaluate for HCM - 3 month(s) ago
View our full Microlesson Series on HCM Playlist: bit.ly/3qixWyfThe American Society of Echocardiography offers in-depth education on cardiovascular ultrasou…
Source: www.youtube.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#DidYouKnow we have an entire Microlesson Series on HCM, comprised of 13 videos (and counting) that dive into all things #HCM? View them all on our YouTube channel: https://t.co/ao4TNZv2CN https://t.co/7ZS02J74je
-
-
Mashup Score: 3Cardiomyopathy & Cardio-Oncology CME - 3 month(s) ago
Focus on cardiomyopathy and cardiovascular health of cancer survivors.
Source: Scripps HealthCategories: Cardiologists, Latest HeadlinesTweet-
Thrilled about our upcoming Scripps Cardiomyopathies and Cardio-Oncology conference this Sep 23 in San Diego! ☀️ Topics will include #amyloid #sarcoid #HCM #geneticCM #cardioonc 🙌🫀 Virtual and in-person. Register here: https://t.co/jyZX5Zkl1k https://t.co/FjJqLqLdfF
-
-
Mashup Score: 0Dr Milind Desai Highlights New Findings From VALOR-HCM Trial - 3 month(s) ago
After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.
Source: www.ajmc.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In this @AJMC_Journal interview, Dr Milind Desai at the @ClevelandClinic discusses highlights from the VALOR-HCM trial in patients with advanced symptoms of hypertrophic obstructive #cardiomyopathy (#HCM). Watch here: https://t.co/VTEHZrMTGE https://t.co/fSxgzfXRsh
-
-
Mashup Score: 0
Expanding Development Program to Assess Potential of Aficamten in Additional Patient Population to Inform Increased Utility of Cardiac Myosin Inhibition SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (A ssessment C omparing A ficamten to Placebo on C ardiac Endpoints I n A dults with Non-Obstructive HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Source: ir.cytokinetics.comCategories: Cardiologists, Latest HeadlinesTweet-
We have some more details on ACACIA-HCM, aficamten in non-obstructive #HCM We presented the primary data in March 2023 (phase II REDWOOD-HCM Cohort 4). Just shy of 6 months later, the phase III kicks off. Tremendous effort by many. https://t.co/8HSfJrgnrr #CardioTwitter
-
-
Mashup Score: 0Home - 3 month(s) ago
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease; however only 1 in 7 patients are diagnosed. Under-recognition of HCM and varied clinical presentation can cause diagnosis delays and misdiagnoses, thereby putting patients at greater risk of cardiovascular events. HCM is no longer a mystery. Evolving guideline recommendations have unlocked the potential for more timely diagnosis and advanced knowledge about pathogenesis has ushered in new and emerging therapeutic strategie
Source: na.eventscloud.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
📝 TEST YOUR SKILLS: Join experts November 11th and learn how to recognize the signs and symptoms associated with #HCM. Crack the case by clicking here: https://t.co/hHLgVe0B4s #CardioTwitter #CardioEd #Cardiologist #MedEd #CMEcredits https://t.co/b4bChvy3q0
-
-
Mashup Score: 2Home - 3 month(s) ago
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease; however only 1 in 7 patients are diagnosed. Under-recognition of HCM and varied clinical presentation can cause diagnosis delays and misdiagnoses, thereby putting patients at greater risk of cardiovascular events. HCM is no longer a mystery. Evolving guideline recommendations have unlocked the potential for more timely diagnosis and advanced knowledge about pathogenesis has ushered in new and emerging therapeutic strategie
Source: na.eventscloud.comCategories: Dermatology, Latest HeadlinesTweet-
📝 TEST YOUR SKILLS: Join experts at #AHA23 November 11th and learn how to recognize the signs and symptoms associated with #HCM. Crack the case by clicking here: https://t.co/JBTacye5WY #CardioTwitter #CardioEd #Cardiologist #MedEd #CMEcredits https://t.co/e3GuJKaMJX
-
For kids with #HCM, “We now have the ability to recognize people at high risk, and we have more effective interventions,” says Dr. Jeffrey Geske @MayoClinicCV. https://t.co/WmrAtzhS45 @TIME